ArticleEuropean heart journal. Case reports2025
Isolated tricuspid Libman-Sacks endocarditis in a patient with systemic lupus erythematosus and antiphospholipid syndrome: case report.
Article in European heart journal. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Libman-Sacks endocarditis (LSE) is an immune-mediated, culture-negative valvulopathy complicating systemic lupus erythematosus (SLE) and often amplified by antiphospholipid syndrome (APS). Although classically left-sided, isolated tricuspid involvement is rare. Advanced three-dimensional (3-D) quantification refines tricuspid regurgitation (TR) grading and informs surgical timing. Case summary: A 41-year-old woman with 2-year SLE and triple-positive secondary APS presented with 2 weeks of fever, migratory arthralgia, and a small non-traumatic subarachnoid haemorrhage (SAH). Serial blood cultures were negative. Transthoracic echocardiography showed multiple heterogeneous vegetations (largest 20 × 12 mm) on all tricuspid leaflets; 2-D PISA-EROA was 30 mm², while 3-D vena-contracta area (VCA) measured 0.95 cm², indicating massive TR. Cardiac computed tomography corroborated leaflet thickening and poor coaptation; transoesophageal echocardiography was deferred owing to recent SAH. A Heart Team favoured LSE over infective endocarditis. After high-dose corticosteroids for an SLE flare, surgery was deferred 21 days post-SAH and tricuspid valve replacement with a 31-mm bovine pericardial bioprosthesis was performed. Pathology confirmed sterile platelet-fibrin vegetations. Post-operatively, she received warfarin (target INR 2.5-3.5; heparin bridge), rituximab, hydroxychloroquine, and tapering prednisone. At 3 months, she was asymptomatic (NYHA I) with a competent prosthesis, normal right-sided dimensions, and improved lupus biomarkers. Discussion: This case highlights (i) the need to consider LSE in culture-negative right-sided endocarditis among SLE/APS patients; (ii) the clinical utility of 3-D VCA to reconcile discrepant 2-D measures and substantiate surgical indication; (iii) peri-operative strategies after recent SAH (timing and anticoagulation); and (iv) rationale for a bioprosthesis in the low-flow tricuspid position given thrombogenicity of mechanical valves, alongside lifelong vitamin K antagonist therapy mandated by APS. Early multimodality imaging, Heart Team decision-making, timely surgery, and optimized immunomodulation can yield excellent outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.